Please assess the completion status of the following clinical trial:

Trial Title: Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary.~* Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing while on a platinum-based chemotherapy)~* At least treated with one line of platinum-based chemotherapy~* Female, age ≥18 years and ≤70 years, signed informed consent.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version~* Patients must have a life expectancy of at least 3 months.~* Patients must have adequate organ function as defined by the following criteria:~  * White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10\^9/L~ * Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN~ * Serum creatinine ≤ 1 x ULN~Exclusion Criteria:~* Had prior exposure to apatinib or has known allegies to any of the excipients.~* History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.~* Patients with QT interval prolongation~* Serious, non-healing wound, active ulcer, bowel obstruction.~* History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1~* Evidence of bleeding diathesis or coagulopathy~* Inadequately controlled hypertension~* Major surgical procedure within 28 days prior to Day 1~* Symptomatic central nervous system (CNS) metastasis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib + Etoposide (Type: EXPERIMENTAL): Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).